Mariia S. Fadeeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariia S. Fadeeva has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry E. Pershin
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
18 shared publications - Michael Aleksandrovich Maschan
National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia
13 shared publications - Victoria A. Vedmedskaia
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
10 shared publications - A Yur'EVna Shcherbina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
9 shared publications - Oiuna B. Lodoeva
Dmitry Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology 1 , Moscow
8 shared publications - Ekaterina A. Malakhova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Moscow Russia
7 shared publications
Latest Publications
- 11 May 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
Diagnostic workflow for X‐linked agammaglobulinemia integrating BTK expression and B‐cell maturation analysis by flow cytometry
X‐linked agammaglobulinemia (XLA) is most often caused by impaired Bruton's tyrosine kinase (BTK) function. Rapid laboratory support is needed when genetic findings are inconclusive or pending. We developed a flow‐cytometric assay to quantify intracellular BTK protein in monocytes, aiding the diagnosis of XLA. A stain index (SI) reference range was established using healthy donors ( n = 25; SI median 1.14, range 1.01–1.66). ROC analysis defined a diagnostic cutoff of SI = 1.79, providing 95% sensitivity and 100% specificity compared to patients with pathogenic BTK variants ( n = 40). Using this cutoff, abnormal BTK expression was detected in 38/40 genetically confirmed XLA patients. All patients with variants of uncertain/likely pathogenic significance ( n = 17) had SI values above the cutoff. Bone marrow analysis in a patient subset showed a developmental arrest at the Pre‐BI stage. The assay offers a rapid, clinically applicable readout to support XLA diagnosis and carrier evaluation in females, effectively complementing genetic testing.
- 11 May 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
Diagnostic workflow for X‐linked agammaglobulinemia integrating BTK expression and B‐cell maturation analysis by flow cytometry
X‐linked agammaglobulinemia (XLA) is most often caused by impaired Bruton's tyrosine kinase (BTK) function. Rapid laboratory support is needed when genetic findings are inconclusive or pending. We developed a flow‐cytometric assay to quantify intracellular BTK protein in monocytes, aiding the diagnosis of XLA. A stain index (SI) reference range was established using healthy donors ( n = 25; SI median 1.14, range 1.01–1.66). ROC analysis defined a diagnostic cutoff of SI = 1.79, providing 95% sensitivity and 100% specificity compared to patients with pathogenic BTK variants ( n = 40). Using this cutoff, abnormal BTK expression was detected in 38/40 genetically confirmed XLA patients. All patients with variants of uncertain/likely pathogenic significance ( n = 17) had SI values above the cutoff. Bone marrow analysis in a patient subset showed a developmental arrest at the Pre‐BI stage. The assay offers a rapid, clinically applicable readout to support XLA diagnosis and carrier evaluation in females, effectively complementing genetic testing.
- 16 February 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (3) , 201-220
Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort
The dihydrorhodamine‐123 flow cytometry (DHR FC) assay is used to diagnose chronic granulomatous disease (CGD). This study presents the experience of a single center with the DHR FC assay in a large cohort to evaluate its applications and limitations. A total of 179 subjects were included in the study for CGD diagnosis, X‐linked CGD (X‐CGD) carrier determination, and post‐hematopoietic stem cell transplantation (HSCT) chimerism monitoring. We performed the DHR FC assay using a standardized protocol, with additional intracellular myeloperoxidase (MPO) staining for borderline cases. The DHR FC assay demonstrated high diagnostic accuracy. PMA stimulation detected 94% of CGD cases. E. coli stimulation identified all CGD cases, including atypical EROS‐deficient ( CYBC1 ) patients (4.3% of the cohort) who exhibited residual reactive oxygen species production (median SI PMA = 40 vs. E. coli = 24). Genetic confirmation revealed that 82% of CGD patients had X‐CGD ( CYBB ), and 18% had autosomal recessive CGD ( CYBA / NCF1 / NCF2 / CYBC1 ) forms. Borderline results were clarified by MPO staining, which diagnosed three MPO‐deficient cases. The assay reliably identified 43 X‐CGD carriers out of 45 suspected cases and showed a strong correlation with the real‐time quantitative polymerase chain reaction for HSCT chimerism monitoring ( r = 0.78, p < 0.0001). The DHR FC assay is a rapid and reliable diagnostic tool for CGD, providing results within hours. Its applications extend to X‐CGD carrier detection and post‐HSCT chimerism monitoring. Dual‐stimulant protocols (PMA + E. coli ) and MPO staining enhance diagnostic accuracy. These findings support the use of the DHR FC assay as a versatile and essential tool in CGD management.
- 16 February 2026
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 110 (3) , 201-220
Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort
The dihydrorhodamine‐123 flow cytometry (DHR FC) assay is used to diagnose chronic granulomatous disease (CGD). This study presents the experience of a single center with the DHR FC assay in a large cohort to evaluate its applications and limitations. A total of 179 subjects were included in the study for CGD diagnosis, X‐linked CGD (X‐CGD) carrier determination, and post‐hematopoietic stem cell transplantation (HSCT) chimerism monitoring. We performed the DHR FC assay using a standardized protocol, with additional intracellular myeloperoxidase (MPO) staining for borderline cases. The DHR FC assay demonstrated high diagnostic accuracy. PMA stimulation detected 94% of CGD cases. E. coli stimulation identified all CGD cases, including atypical EROS‐deficient ( CYBC1 ) patients (4.3% of the cohort) who exhibited residual reactive oxygen species production (median SI PMA = 40 vs. E. coli = 24). Genetic confirmation revealed that 82% of CGD patients had X‐CGD ( CYBB ), and 18% had autosomal recessive CGD ( CYBA / NCF1 / NCF2 / CYBC1 ) forms. Borderline results were clarified by MPO staining, which diagnosed three MPO‐deficient cases. The assay reliably identified 43 X‐CGD carriers out of 45 suspected cases and showed a strong correlation with the real‐time quantitative polymerase chain reaction for HSCT chimerism monitoring ( r = 0.78, p < 0.0001). The DHR FC assay is a rapid and reliable diagnostic tool for CGD, providing results within hours. Its applications extend to X‐CGD carrier detection and post‐HSCT chimerism monitoring. Dual‐stimulant protocols (PMA + E. coli ) and MPO staining enhance diagnostic accuracy. These findings support the use of the DHR FC assay as a versatile and essential tool in CGD management.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 15-30
Features of diagnosis and management of patients with autoimmune lymphoproliferative syndrome caused by somatic defects of the FAS gene
Introduction. Autoimmune lymphoproliferative syndrome (ALPS) is an inborn error of immunity with impaired FAS-mediated apoptosis. The disease responds well to therapy with the mTORC1-inhibitor sirolimus (SRL). The diagnosis of ALPS is based on the European Society for Immunodeficiencies (ESID) diagnostic criteria, which include the main clinical manifestations in combination mainly with an increased level of double-negative T-lymphocytes (DNT) with the CD3+TCRαβ+CD4–CD8–-phenotype. Most cases of ALPS are caused by germinal mutations in the FAS gene, however, somatic changes in this gene (ALPS-sFAS) can be detected in 15–20% of patients. Aim: to analyze the diagnostic features and clinical presentation before and during SRL treatment in patients with ALPS-sFAS. Materials and methods. In our cohort of patients (n = 6), we analyzed main clinical data (clinical presentation, laboratory and instrumental data), the stages of genetic search and response to SRL therapy. We observed an early onset of the disease (median of 1.7 years), with delayed clinical (median of 3.7 years) and genetic (median of 6.2 years) diagnosis. Results. At the initial examination, only 67% of the patients met the ESID criteria. In 50% of cases with DNT levels 9.9%, somatic mutations in the FAS gene were detected in whole blood DNA, in other cases, we analyzed DNA from sorted DNT cells. All of our patients had previously undescribed somatic mutations in the FAS gene. Our experience of SRL treatment in patients with ALPS-sFAS has been more than 10 years. We observed a good clinical response, as well as continued remission of the disease at a reduced dose of SRL (1.5 mg/m2). In 67% of cases, various adverse events were observed when the SRL dose was 1.5 mg/m2. Conclusion. The obtained results demonstrate the complexity of diagnosis and the need for concern regarding ALPS-cFAS, taking into account the effectiveness of pathogenetic therapy, as well as the importance of a personalized approach in molecular genetic verification of the diagnosis.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 15-30
Open AccessFeatures of diagnosis and management of patients with autoimmune lymphoproliferative syndrome caused by somatic defects of the FAS gene
Introduction. Autoimmune lymphoproliferative syndrome (ALPS) is an inborn error of immunity with impaired FAS-mediated apoptosis. The disease responds well to therapy with the mTORC1-inhibitor sirolimus (SRL). The diagnosis of ALPS is based on the European Society for Immunodeficiencies (ESID) diagnostic criteria, which include the main clinical manifestations in combination mainly with an increased level of double-negative T-lymphocytes (DNT) with the CD3+TCRαβ+CD4–CD8–-phenotype. Most cases of ALPS are caused by germinal mutations in the FAS gene, however, somatic changes in this gene (ALPS-sFAS) can be detected in 15–20% of patients. Aim: to analyze the diagnostic features and clinical presentation before and during SRL treatment in patients with ALPS-sFAS. Materials and methods. In our cohort of patients (n = 6), we analyzed main clinical data (clinical presentation, laboratory and instrumental data), the stages of genetic search and response to SRL therapy. We observed an early onset of the disease (median of 1.7 years), with delayed clinical (median of 3.7 years) and genetic (median of 6.2 years) diagnosis. Results. At the initial examination, only 67% of the patients met the ESID criteria. In 50% of cases with DNT levels 9.9%, somatic mutations in the FAS gene were detected in whole blood DNA, in other cases, we analyzed DNA from sorted DNT cells. All of our patients had previously undescribed somatic mutations in the FAS gene. Our experience of SRL treatment in patients with ALPS-sFAS has been more than 10 years. We observed a good clinical response, as well as continued remission of the disease at a reduced dose of SRL (1.5 mg/m2). In 67% of cases, various adverse events were observed when the SRL dose was 1.5 mg/m2. Conclusion. The obtained results demonstrate the complexity of diagnosis and the need for concern regarding ALPS-cFAS, taking into account the effectiveness of pathogenetic therapy, as well as the importance of a personalized approach in molecular genetic verification of the diagnosis.
- Open Access
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 14-26
Preclinical development of a protocol for the manufacturing of anti-CD5 CAR-T lymphocytes for the treatment of T-lineage acute lymphoblastic leukemia and lymphoma
The development of cell therapy methods for T-lineage acute lymphoblastic leukemia remains a relevant clinical challenge. The current study presents a preclinical stage of anti-CD5 CAR-T cell development without the use of additional genetic modifications, relying on down-regulation of CD5. The resulting cell products demonstrated sufficient expansion rates and CAR expression levels, the predominance of the Tem phenotype (CD197–CD45RA–) and low expression of exhaustion markers (PD-1, CD57, TIGIT). The antitumor function was confirmed both in vitro through the assessment of degranulation, cytokine production, and cytotoxicity against the Jurkat cell line, and in vivo through the evaluation of CD5+ leukemia elimination in a murine model. The data obtained may serve as a basis for the development of a clinical manufacturing protocol for anti-CD5 CAR-T cells. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 14-26
Open AccessPreclinical development of a protocol for the manufacturing of anti-CD5 CAR-T lymphocytes for the treatment of T-lineage acute lymphoblastic leukemia and lymphoma
The development of cell therapy methods for T-lineage acute lymphoblastic leukemia remains a relevant clinical challenge. The current study presents a preclinical stage of anti-CD5 CAR-T cell development without the use of additional genetic modifications, relying on down-regulation of CD5. The resulting cell products demonstrated sufficient expansion rates and CAR expression levels, the predominance of the Tem phenotype (CD197–CD45RA–) and low expression of exhaustion markers (PD-1, CD57, TIGIT). The antitumor function was confirmed both in vitro through the assessment of degranulation, cytokine production, and cytotoxicity against the Jurkat cell line, and in vivo through the evaluation of CD5+ leukemia elimination in a murine model. The data obtained may serve as a basis for the development of a clinical manufacturing protocol for anti-CD5 CAR-T cells. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.
- Open Access
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 27-37
Experience in developing and scaling a protocol for NK lymphocyte enriched cellular product manufacturing for clinical application
For NK lymphocyte-enriched biomedical cell product is a pressing issue in clinical biotechnology. Based on numerous scientific and clinical studies, we have settled on the NK lymphocyte expansion protocol with a modified feeder line K562 and peripheralblood mononuclear cells as a starting fraction, not including CD3+ lymphocyte depletion step. In this paper, we present the results of a validation process of NK lymphocyte-enriched biomedical cell product manufacturing. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The resulting cell productsmet all stated quality control criteria, contained a high percentage of NK cells, and demonstrated strong cytotoxic activity against the THP-1 and Jeko-I cell lines. Expansion folds allowed us to achieve the desired clinical dosage in all processes. Thesurface marker expression profile of the expanded NK cells corresponded to an activated and highly proliferative phenotype. The residual lymphocytes were represented mainly by T cells with an effector phenotype, and a significant decrease in TCRab percentage was observed compared to the initial fraction. These data provide the basis for a clinical study of the feasibility and safety of the infusions of the cellular products produced according to this protocol for pediatric refractory leukemia treatment.
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 27-37
Open AccessExperience in developing and scaling a protocol for NK lymphocyte enriched cellular product manufacturing for clinical application
For NK lymphocyte-enriched biomedical cell product is a pressing issue in clinical biotechnology. Based on numerous scientific and clinical studies, we have settled on the NK lymphocyte expansion protocol with a modified feeder line K562 and peripheralblood mononuclear cells as a starting fraction, not including CD3+ lymphocyte depletion step. In this paper, we present the results of a validation process of NK lymphocyte-enriched biomedical cell product manufacturing. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The resulting cell productsmet all stated quality control criteria, contained a high percentage of NK cells, and demonstrated strong cytotoxic activity against the THP-1 and Jeko-I cell lines. Expansion folds allowed us to achieve the desired clinical dosage in all processes. Thesurface marker expression profile of the expanded NK cells corresponded to an activated and highly proliferative phenotype. The residual lymphocytes were represented mainly by T cells with an effector phenotype, and a significant decrease in TCRab percentage was observed compared to the initial fraction. These data provide the basis for a clinical study of the feasibility and safety of the infusions of the cellular products produced according to this protocol for pediatric refractory leukemia treatment.
- 13 July 2024
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 69 (3) , 125-131
A rare variant of primary immunodeficiency with a STAT1 GOF defect in the practice of a pulmonologist
Chronic mucocutaneous candidiasis is a complication occurring in patients with congenital immune disorders, characterized by recurrent infections of the skin, nails, and mucous membranes caused by C. albicans. The STAT1 gain of function (GOF) defect is a primary immunodeficiency condition resulting from heterozygous gain of function mutations in the STAT1 gene. STAT1 is a regulatory transcription factor and a key component of the JAK-STAT pathway mediating interferon-α/β/γ signaling. GOF mutations in the STAT1 gene lead to hyperphosphorylation of the protein of the same name and increased signaling along the JAK-STAT pathway, which also leads to impaired development of type 17 T helper cells (Th17). This disease most often debuts in childhood, and clinically, it is characterized by chronic mucocutaneous candidiasis, multiorgan autoimmune complications and an increased risk of infectious complications. The article describes the clinical observation of a girl with a rare variant of primary immunodeficiency STAT1 GOF.
- 13 July 2024
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 69 (3) , 125-131
A rare variant of primary immunodeficiency with a STAT1 GOF defect in the practice of a pulmonologist
Chronic mucocutaneous candidiasis is a complication occurring in patients with congenital immune disorders, characterized by recurrent infections of the skin, nails, and mucous membranes caused by C. albicans. The STAT1 gain of function (GOF) defect is a primary immunodeficiency condition resulting from heterozygous gain of function mutations in the STAT1 gene. STAT1 is a regulatory transcription factor and a key component of the JAK-STAT pathway mediating interferon-α/β/γ signaling. GOF mutations in the STAT1 gene lead to hyperphosphorylation of the protein of the same name and increased signaling along the JAK-STAT pathway, which also leads to impaired development of type 17 T helper cells (Th17). This disease most often debuts in childhood, and clinically, it is characterized by chronic mucocutaneous candidiasis, multiorgan autoimmune complications and an increased risk of infectious complications. The article describes the clinical observation of a girl with a rare variant of primary immunodeficiency STAT1 GOF.
- Open Access
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 48-59
Experience in manufacturing a haploidentical biomedical cell product enriched with regulatory T-lymphocytes
Graft-versus-host disease (GVHD) remains the main life-threatening immunologic complication of hematopoietic stem cell transplantation. Despite modern pharmacological approaches for preventing and treating GVHD, there remains a need for new approaches to cure GVHD. Currently, more and more clinical experience is emerging globally in the field of using regulatory T-cell (Treg) therapies for the treatment of refractory GVHD. Manufacturing cell products for Treg therapies has a wide range of protocol variations. We have developed an approach of Treg manufacturing for cell therapy and present data from our experience in manufacturing a haploidentical Treg cell product by combining CD25+ immunomagnetic selection with closed system flowbased cell sorting methods. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study describes the processes of producing 9 Treg cell products. According to the manufacturing protocol described here, it is possible to obtain a cell product that meets the quality control requirements necessary for approval for clinical use. Quality control includes the assessment of the cell composition, viability, and microbiological safety of the product, and is performed at all major stages of production. The final cell product is characterized by consistently high levels of FoxP3-expressing Treg (median: 98%), with a median cell viability of 99.1%, and has a high potential for functional efficacy. Thus, the protocol for producing Treg cell products by combining CD25+ immunomagnetic selection with flow cytometry-based cell sorting methods can be used for the clinical treatment of GVHD.
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 48-59
Open AccessExperience in manufacturing a haploidentical biomedical cell product enriched with regulatory T-lymphocytes
Graft-versus-host disease (GVHD) remains the main life-threatening immunologic complication of hematopoietic stem cell transplantation. Despite modern pharmacological approaches for preventing and treating GVHD, there remains a need for new approaches to cure GVHD. Currently, more and more clinical experience is emerging globally in the field of using regulatory T-cell (Treg) therapies for the treatment of refractory GVHD. Manufacturing cell products for Treg therapies has a wide range of protocol variations. We have developed an approach of Treg manufacturing for cell therapy and present data from our experience in manufacturing a haploidentical Treg cell product by combining CD25+ immunomagnetic selection with closed system flowbased cell sorting methods. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study describes the processes of producing 9 Treg cell products. According to the manufacturing protocol described here, it is possible to obtain a cell product that meets the quality control requirements necessary for approval for clinical use. Quality control includes the assessment of the cell composition, viability, and microbiological safety of the product, and is performed at all major stages of production. The final cell product is characterized by consistently high levels of FoxP3-expressing Treg (median: 98%), with a median cell viability of 99.1%, and has a high potential for functional efficacy. Thus, the protocol for producing Treg cell products by combining CD25+ immunomagnetic selection with flow cytometry-based cell sorting methods can be used for the clinical treatment of GVHD.
- Open Access
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 128-139
Comparative characterization of the cell composition and functional properties of anti-CD19 biomedical cell products manufactured using the CliniMACS Prodigy and G-Rex platforms
Today, the use of anti-CD19 biomedical cell products (BMCPs) for the treatment of B-cell malignancies yields impressive results and is becoming ever more popular. Several bioreactors have been developed that allow the manufacturing of high-quality cell products for clinical use. Choosing an appropriate bioreactor is an important step in this process. The aim of this study was to characterize and compare immunophenotypic and functional properties of anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system (Miltenyi Biotec, Germany) and the manual G-Rex 10M-CS platform (Wilson Wolf, USA). The manufacturing of BMCPs and subsequent CAR T-cell therapy were carried out at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia. We used T cells from patients who had undergone HSCT as well as from autologous and allogeneic donors. In this study, we employed 26 anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system in accordance with the GMP requirements as well as 25 cell products produced with the G-Rex platform. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Quality control was ensured throughout the entire manufacturing cycle and included assessment of cell composition and survival, transduction efficiency, cell expansion, expression of exhaustion markers, and CD19-specific antitumor activity. Our research showed that both manufacturing platforms generate stable high-quality products with sufficient cell expansion, viability and T cell transduction for subsequent CAR-T therapy. However, the median transduction efficiency of the BMCPs produced using the CliniMACS Prodigy platform was statistically significantly higher than that of the BMCPs manufactured using the G-Rex bioreactor (41% vs 26%). The study showed that in the anti-CD19 BMCPs, there was a predominance of Tcm subpopulation over Tem subpopulation, a low expression of exhaustion markers and a pronounced CD19-specific activity. Nevertheless, the percentage of Tcm cells in the BMCPs manufactured using the CliniMACS Prodigy platform was statistically significantly higher than in the BMCPs produced using the G-Rex bioreactor (86.7% CD8+ Tcm cells and 82.3% CD4+ Tcm cells for CliniMACS Prodigy vs 69.0% CD8+ Tcm cells and 72.0% CD4+ Tcm cells for G-Rex). Despite the lower number of anti-CD19 CAR-T cells in the final cell products obtained with the G-Rex bioreactor, in all processes this amount was sufficient for subsequent CAR-T therapy. Thus, the CliniMACS Prodigy and G-Rex platforms can be used to produce high-quality anti-CD19 BMCPs.
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 128-139
Open AccessComparative characterization of the cell composition and functional properties of anti-CD19 biomedical cell products manufactured using the CliniMACS Prodigy and G-Rex platforms
Today, the use of anti-CD19 biomedical cell products (BMCPs) for the treatment of B-cell malignancies yields impressive results and is becoming ever more popular. Several bioreactors have been developed that allow the manufacturing of high-quality cell products for clinical use. Choosing an appropriate bioreactor is an important step in this process. The aim of this study was to characterize and compare immunophenotypic and functional properties of anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system (Miltenyi Biotec, Germany) and the manual G-Rex 10M-CS platform (Wilson Wolf, USA). The manufacturing of BMCPs and subsequent CAR T-cell therapy were carried out at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia. We used T cells from patients who had undergone HSCT as well as from autologous and allogeneic donors. In this study, we employed 26 anti-CD19 BMCPs manufactured using the automated CliniMACS Prodigy system in accordance with the GMP requirements as well as 25 cell products produced with the G-Rex platform. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Quality control was ensured throughout the entire manufacturing cycle and included assessment of cell composition and survival, transduction efficiency, cell expansion, expression of exhaustion markers, and CD19-specific antitumor activity. Our research showed that both manufacturing platforms generate stable high-quality products with sufficient cell expansion, viability and T cell transduction for subsequent CAR-T therapy. However, the median transduction efficiency of the BMCPs produced using the CliniMACS Prodigy platform was statistically significantly higher than that of the BMCPs manufactured using the G-Rex bioreactor (41% vs 26%). The study showed that in the anti-CD19 BMCPs, there was a predominance of Tcm subpopulation over Tem subpopulation, a low expression of exhaustion markers and a pronounced CD19-specific activity. Nevertheless, the percentage of Tcm cells in the BMCPs manufactured using the CliniMACS Prodigy platform was statistically significantly higher than in the BMCPs produced using the G-Rex bioreactor (86.7% CD8+ Tcm cells and 82.3% CD4+ Tcm cells for CliniMACS Prodigy vs 69.0% CD8+ Tcm cells and 72.0% CD4+ Tcm cells for G-Rex). Despite the lower number of anti-CD19 CAR-T cells in the final cell products obtained with the G-Rex bioreactor, in all processes this amount was sufficient for subsequent CAR-T therapy. Thus, the CliniMACS Prodigy and G-Rex platforms can be used to produce high-quality anti-CD19 BMCPs.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (3)
Development and validation of a method for assessing STAT1 protein phosphorylation as a diagnostic tool for patients with defects in the conforming gene
Разработка и валидация метода оценки фосфорилирования белка STAT1 в качестве инструмента диагностики пациентов с дефектами соответствующего гена
- 1 January 2024
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 45 (3)
Open AccessDevelopment and validation of a method for assessing STAT1 protein phosphorylation as a diagnostic tool for patients with defects in the conforming gene
Разработка и валидация метода оценки фосфорилирования белка STAT1 в качестве инструмента диагностики пациентов с дефектами соответствующего гена